度拉糖肽治疗2型糖尿病的临床研究进展被引量：37

Research progress on clinical research of dulaglutide in treatment of type 2 diabetes

导出

摘要目前,我国老年糖尿病患者的发病人数越来越多。GLP-1受体激动剂是一类新型作用靶点的降糖药物。新型长效GLP-1受体激动剂度拉糖肽具有改善血糖水平、降低患者体质量、每周注射1次的临床应用特点,同时该药物也具有胃肠道不适等相关的不良反应。对度拉糖肽在临床研究中的应用现状进行综述,供临床医生参考。 At present,the number of older patients with diabetes is increasing in China.GLP-1 receptor agonist is a new kind of antihyperglycemic medication.The new long-acting GLP-1 receptor agonist,dulaglutide,has been shown to control the blood glucose level,reduce the bodyweight of patients,and has been injected once a week in clinical practice.Meanwhile,the drug has also been associated with gastrointestinal discomfort and other adverse reactions.The current situation of the application of dulaglutide in clinic is reviewed in this paper,and provide reference for clinicians.

作者郑晓辉宋轶萱史桂玲赵振营周存霞张继红孙秀颖 ZHENG Xiao-hui;SONG Yi-xuan;SHI Gui-ling;ZHAO Zhen-ying;ZHOU Cun-xia;ZHANG Ji-hong;SUN Xiu-ying(Deparment of Pharmacy,Tianjin Union Medical Center,Tianjin 300121,China;Deparment of Endocrinology,Tianjin Union Medical Center,Tianjin 300121,China)

机构地区天津市人民医院药学部天津市人民医院内分泌科

出处《现代药物与临床》 CAS 2020年第1期184-188,共5页 Drugs & Clinic

基金天津市“131”创新型人才培养工程项目.

关键词度拉糖肽 GLP-1受体激动剂 2型糖尿病临床应用 dulaglutide GLP-1 receptor agonist type 2 diabetes clinical application

分类号 R587.1 [医药卫生—内分泌]

作者简介郑晓辉(1987—),女,硕士,主管药师,主要从事临床药学研究。E-mail:zheng_xiaohui_ok@126.com;通信作者:孙秀颖(1973—),女,硕士,副主任药师。E-mail:rmyyyjk2096@126.com

引文网络
相关文献

参考文献2

1陈培幸,肖拥军,曹春来,黄亮.2型糖尿病治疗新药——度拉糖肽研究进展[J].现代医药卫生,2014,30(21):3247-3249. 被引量：4
2吴桂堂,秦伟,王海久.胰高血糖素样肽1研究进展[J].医学综述,2011,17(21):3236-3240. 被引量：6

二级参考文献47

1杨扬,张义栋,姜吉文.刺五加叶皂甙对GLP-1分泌影响的实验研究[J].福建中医药,2004,35(3):38-41. 被引量：11
2李艳君,武艳丽,云长海,张维烨,亓卫东.消渴汤方剂对Ⅱ型糖尿病大鼠GLP-1分泌的影响[J].解剖科学进展,2005,11(1):43-44. 被引量：13
3周琼,欧阳金芝,张木勋,张建华,杨雁.胰升糖素样肽-1对高游离脂肪酸诱导的胰岛β细胞凋亡作用的研究[J].临床内科杂志,2007,24(4):275-277. 被引量：2
4Orskov C. Glucagon-like peptide-1, a new hormone of the entero- insular axis [ J ]. Diabetlogia, 1992,35 ( 8 ) :701-711.
5Schmidt PT, Naslund E, Gryback P, et al. Peripheral administration of GLP-2 to humans has no effect on gastric empting or satiety[J]. Regul Pept,2003,116 ( 1/3 ) :21-25.
6Vahit P,Paty BW,Faller BD,et al. Effects of GLP-l-(7-36) NH2, GLP-l-(7-37 ), andGLP-1-(9-36)NH2 on intrave-nous glucose tolerance and glucose-induced insulin secretion in healthy humans [ J ]. J Clin Endocrinol Metab, 2003,88 (4) : 1772 -1779.
7Lim G, Brubaker P. Glucagon-like peptide 1 secretion by the L- cell:The view from within [J]. Diabetes, 2006,55 (Suppl 2): S70-S77.
8De Leon DD, Crutchlow MF, Ham JY, et al. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus [ J]. Int J Biochem Cell Bio1,2006,38 (5/6) :845-859.
9D'Alessio DA,Sandoval DA, Seeley ILl. New ways in which GLP- 1 can regulate glucose homeostasis [ J ]. J Clin Invest, 2005,115 (12) :3406-3408.
10Holst JJ. Glucagon-like peptide 1 ( GLP-1 ) : an intestinal hormone, signaling nutritional abundance,with an unusual "therapeutic poten- tial[J]. Trands Endocr Met,1999,10(6) :229-235.